APA

Devasthale P., Wang Y., Wang W., Fevig J., Feng J., Wang A., Harrity T., Egan D., Morgan N., Cap M., Fura A., Klei H. E., Kish K., Weigelt C., Sun L., Levesque P., Moulin F., Li Y., Zahler R., Kirby M. S. & Hamann L. G. (20131126). Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). : Journal of medicinal chemistry.

Chicago

Devasthale Pratik, Wang Ying, Wang Wei, Fevig John, Feng JianXin, Wang Aiying, Harrity Tom, Egan Don, Morgan Nathan, Cap Michael, Fura Aberra, Klei Herbert E, Kish Kevin, Weigelt Carolyn, Sun Lucy, Levesque Paul, Moulin Frederic, Li Yi-Xin, Zahler Robert, Kirby Mark S and Hamann Lawrence G. 20131126. Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). : Journal of medicinal chemistry.

Harvard

Devasthale P., Wang Y., Wang W., Fevig J., Feng J., Wang A., Harrity T., Egan D., Morgan N., Cap M., Fura A., Klei H. E., Kish K., Weigelt C., Sun L., Levesque P., Moulin F., Li Y., Zahler R., Kirby M. S. and Hamann L. G. (20131126). Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). : Journal of medicinal chemistry.

MLA

Devasthale Pratik, Wang Ying, Wang Wei, Fevig John, Feng JianXin, Wang Aiying, Harrity Tom, Egan Don, Morgan Nathan, Cap Michael, Fura Aberra, Klei Herbert E, Kish Kevin, Weigelt Carolyn, Sun Lucy, Levesque Paul, Moulin Frederic, Li Yi-Xin, Zahler Robert, Kirby Mark S and Hamann Lawrence G. Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). : Journal of medicinal chemistry. 20131126.